Quiet NeuroPhage nabs $12.4M in Series B round

Tue, 03/01/2011 - 4:36am
Mass High Tech: The Journal of New England Technology

Cambridge-based NeuroPhage Pharmaceuticals Inc. has landed $12.4 million in a Series B round of funding led by MerieuxDeveloppement, the investment arm of French industrial holding company InstitutMerieux, with Shire LLC as a new investor and participation from existing investors.

This latest funding brings the total raise by NeuroPhage to $19.6 million since it launched in December of 2006, based on intellectual property licensed from professor Beka Solomon’s laboratory at Tel Aviv University. The company is led by co-founder Jonathan Solomon, a former Medtronic executive, who serves as president and CEO, according to the NeuroPhage website. Biogen Idec Inc. veteran Richard Fisher serves as chief scientific officer.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.